
Dare Bioscience (NASDAQ:DARE) is expanding its direct commercialization efforts while advancing late-stage studies of a hormone-free contraceptive and a potential treatment for human papillomavirus infection, CEO Sabrina Johnson said at a company presentation.
Johnson described 2026 and the move into 2027 as an important period for the women’s health company. Its vaginal probiotic, Flora Sync LF5, is already on the market, while its DARE to PLAY Sildenafil Cream is expected to begin dispensing as a compounded product later this year, she said.
Two clinical readouts are expected next year: Phase III data for Ovaprene, a once-a-month hormone-free contraceptive, and Phase II data for DARE-HPV. Johnson also said the company hopes to bring its menopause hormone therapy product to market next year.
Commercial Products and Distribution
Flora Sync LF5, launched during the summer, is a vaginally delivered probiotic taken once daily for three days. Johnson said a published randomized controlled trial showed that the product restored the vaginal microbiome in 96% of patients, with 90% maintaining that result two weeks later.
Daré is sampling the product to health care providers, supporting clinics that want to sell it directly and making it available online, she said.
DARE to PLAY Sildenafil Cream contains the same active ingredient found in the erectile dysfunction drug Viagra. Johnson said the formulation was designed to increase blood flow in women and has been clinically studied for physical arousal response.
The company is working toward FDA approval but plans to make the cream available first through a 503B compounding arrangement. Johnson said prescriptions are already being accepted and dispensing should begin later this year. The compounded product is not FDA-approved; Johnson said the outsourcing facility must follow manufacturing quality standards and is subject to FDA inspection and reporting.
Daré is using its online Daré Health Hub, provider relationships, telehealth and social media to reach customers. Johnson said the platform could also support cross-selling as additional products become available.
Clinical Pipeline and Funding
Ovaprene is in a Phase III registration trial, with enrollment expected to finish this year and data expected next year. Johnson said two data safety monitoring board reviews have been positive and that study data so far continue to support a projected typical-use effectiveness rate of 86% to 91%, based on the earlier Phase II study.
DARE-HPV combines the antivirals lopinavir and ritonavir in a formulation optimized for vaginal delivery. Johnson said the Phase II trial is funded by an ARPA-H grant and is expected to produce data next year.
The company is also pursuing a 503B launch strategy for DARE to RECLAIM, its once-a-month vaginal ring combining estradiol and progesterone, while continuing work toward registration. Johnson said earlier Phase I/II data showed the ring delivered premenopausal estradiol levels and protective progesterone levels.
Daré has brought in more than $75 million in non-dilutive funding, according to Johnson. She said the company has sufficient funding for its current launch efforts and is prioritizing grant-supported development programs, including Ovaprene and DARE-HPV. Daré has also used a Regulation A offering that allowed clinicians, customers and other investors to participate, she said.
About Dare Bioscience (NASDAQ:DARE)
Daré Bioscience, Inc. (NASDAQ: DARE) is a biopharmaceutical company focused on developing and commercializing therapies designed to address unmet needs in women’s health. The company’s research and development activities span contraception, vaginal health, sexual health and reproductive health, with an emphasis on pharmaceutical products and drug-delivery technologies. Daré’s lead commercial product is XACIATO (clindamycin phosphate) vaginal gel 2%, an FDA-approved prescription treatment for bacterial vaginosis in females 12 and older.
